Kindle download - previous pearls
Previous Pearls 2017
Previous Pearls 2016
Previous Pearls 2015
Previous Pearls 2014
Previous Pearls 2013
Previous Pearls 2012
Previous Pearls 2011
Previous Pearls 2010
Previous Pearls 2009
Previous Pearls 2008
Previous Pearls 2007
Previous Pearls 2006
Previous Pearls 2005
Related Critical Care sites
Email / Contribute / Feedback
About us / Editorial team

Friday, February 24, 2017


Q: What is the caveat of measuring fibrinogen level in patients with liver disease? 

Answer:  Liver disease is mostly marked by (acquired) dysfibrinogenemia, not low fibrinogen level. This results in normal fibrinogen levels when measured by immunologic methods. Dysfibrinogenemia can be establish by demonstrating prolong thrombin and reptilase times.

Clinically, this is important as clinicians may get deceived by normal fibrinogen level but patient may continue to bleed due to dysfibrinogenemia.


1.  Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35:667. 

2. Regañón E, Vila V, Aznar J, et al. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 1987; 46:705. 

3. Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994; 14:769.

Tip for finding previous pearl
To find previous pearl - go to 'google', as we archive at google's blogspot.
Type your keyword (like hyperkalemia) followed with icuroom.net

This site is a quick "coffee break" forum for "intensivists" -   trained and dedicated in taking care of  critically ill (ICU) patients !!